This reference work provides comprehensive data about neuroendocrine neoplasms.
Written by some of the most noted experts across 5 continents, this book provides innovative classification and all the recent advances in tumor biology and molecular characterization, as well as in diagnosis, definition of prognosis and treatment of neuroendocrine neoplasia.
This book is a reference tool for practitioners involved in the management of patients, namely oncologists, endocrinologists, gastroenterologists, radiologists, surgeons, pathologists, biologists, as well as other specialists facing patients with neuroendocrine neoplasia because of peculiar aspects (cardiologists, pneumologists, nutritionists, psychologists). It is published as part of the SpringerReference program, which offers access to "living" editions constantly updated through a dynamic peer-review publishing process.
Prof. Antongiulio Faggiano is Full Professor of Endocrinology at the Department of Clinical and Molecular Medicine, Sapienza University, Sant'Andrea University Hospital of Rome. He is a key opinion leader in the field of neuroendocrine neoplasms such as NET and medullary thyroid cancer. He is nationally and internationally recognized as expert in the field of neuroendocrine neoplasms and endocrine tumors, with special interest in the field of therapy with somatostatin analogues and dopamine agonists, targeted therapies, biomarkers for diagnosis, prognosis, and response to therapy. He has been a member of the Advisory Board of the European Neuroendocrine Tumor Society (ENETS), the main international Society of neuroendocrine neoplasms. He has been involved as participating center or PI in several phase 2 and 3 trials for neuroendocrine and thyroid cancer. He is author of more than 300 full papers in international peer-reviewed journals (H-index 55), the most part on neuroendocrine tumors and genetic endocrine syndrome. In 2022, he received the lifetime achievement award of the Italian Society of Endocrinology.
Diego Ferone is Full Professor of Endocrinology at the Department of Internal Medicine and Medical Specialties, Director of the Postgraduate School of Endocrinology and Metabolism, and Chief of the Endocrine Unit at the University of Genova, as well as Director of the Department of Internal Medicina at the San Martino University Hospital in Genova. Currently he is a President of the Italian Endocrine Society (where he also served as Treasurer and General Secretary), Past Secretary of the Italian Society of Andrology and Sexual Medicine, a member of the Advisory Board of the European Neuroendocrine Tumor Society, a past member of the Executive Committee of the European Neuroendocrine Association (ENEA), and a member of several journal Editorial Boards. After obtaining his degree in Medicine and postgraduate degree in Endocrinology and Metabolic Diseases at the Federico II University of Naples (Italy), he received his Ph.D. in Neuroendocrinology at Erasmus University in Rotterdam (Netherlands) supervised by Profs. Steven Lamberts and Leo Hofland. He was awarded Best Young Investigator in 1999 and received the Career Award in 2011 by the Italian Endocrine Society, and the award of Best Italian Researcher in 2010 in the field of neuroendocrine tumors and multiple endocrine neoplasia. He has been constantly involved in studies on the physiopathology and treatment of pituitary and neuroendocrine tumors, physiopathology of somatostatin and dopamine receptors in the immune and neuroendocrine systems, and medical therapy of acromegaly, Cushing's disease, neuroendocrine tumors, and hypopituitarism; he has authored more than 350 peer-reviewed articles. Moreover, he has presented more than 700 lectures at international and national meetings and is author of about 40 book chapters (total impact factor: >600; h-index: 72).
Dr. Simron Singh is a Professor of Medicine at the University of Toronto and a medical oncologist at Odette Cancer Center, Sunnybrook Health Sciences Center in Toronto, Canada. He completed postgraduate training in Internal Medicine at Queens University in Kingston, Ontario, Canada, and Medical Oncology at the University of Toronto. After completing his clinical training, he completed his master's degree in Public Health at Harvard University in Boston, MA, USA. He is a global leader in the field of Neuroendocrine cancers. He has led major practice changing global clinical trials as well as guidelines. Besides being an international sought-after speaker he has published in numerous high-impact journals in this area, including Lancet, Journal of Clinical Oncology, and JAMA. He co-established the Susan Leslie clinic for neuroendocrine cancers--the first of its kind in the region. He is the (incoming) president of the North American Neuroendocrine Society as well as co-head of the Commonwealth Neuroendocrine Tumor Society.
